Current knowledge of bone-derived factor osteocalcin : its role in the management and treatment of diabetes mellitus, osteoporosis, osteopetrosis and inflammatory joint diseases
© 2024. The Author(s)..
Osteocalcin (OC) is the most abundant non-collagenous and osteoblast-secreted protein in bone. It consists of two forms such as carboxylated OC (cOC) and undercarboxylated OC (ucOC). While cOC promotes bone mineralization and increases bone strength, ucOC is regarded an endocrinologically active form that may have several functions in multiple end organs and tissues. Total OC (tOC) includes both of these forms (cOC and ucOC) and is considered a marker of bone turnover in clinical settings. Most of the data on OC is limited to preclinical studies and therefore may not accurately reflect the situation in clinical conditions. For the stated reason, the aim of this review was not only to summarize current knowledge of all forms of OC and characterize its role in diabetes mellitus, osteoporosis, osteopetrosis, inflammatory joint diseases, but also to provide new interpretations of its involvement in the management and treatment of aforementioned diseases. In this context, special emphasis was placed on available clinical trials. Significantly lower levels of tOC and ucOC could be associated with the risk of type 2 diabetes mellitus. On the contrary, tOC level does not seem to be a good indicator of high bone turnover status in postmenopausal osteoporosis, osteoarthritis and rheumatoid arthritis. The associations between several pharmacological drugs used to treat all disorders mentioned above and OC levels have also been provided. From this perspective, OC may serve as a medium through which certain medications can influence glucose metabolism, body weight, adiponectin secretion, and synovial inflammation.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:102 |
|---|---|
| Enthalten in: |
Journal of molecular medicine (Berlin, Germany) - 102(2024), 4 vom: 15. März, Seite 435-452 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Martiniakova, Monika [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
104982-03-8 |
|---|
| Anmerkungen: |
Date Completed 26.03.2024 Date Revised 28.03.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1007/s00109-024-02418-8 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM368534006 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM368534006 | ||
| 003 | DE-627 | ||
| 005 | 20240329000532.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240216s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s00109-024-02418-8 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1353.xml |
| 035 | |a (DE-627)NLM368534006 | ||
| 035 | |a (NLM)38363329 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Martiniakova, Monika |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Current knowledge of bone-derived factor osteocalcin |b its role in the management and treatment of diabetes mellitus, osteoporosis, osteopetrosis and inflammatory joint diseases |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 26.03.2024 | ||
| 500 | |a Date Revised 28.03.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2024. The Author(s). | ||
| 520 | |a Osteocalcin (OC) is the most abundant non-collagenous and osteoblast-secreted protein in bone. It consists of two forms such as carboxylated OC (cOC) and undercarboxylated OC (ucOC). While cOC promotes bone mineralization and increases bone strength, ucOC is regarded an endocrinologically active form that may have several functions in multiple end organs and tissues. Total OC (tOC) includes both of these forms (cOC and ucOC) and is considered a marker of bone turnover in clinical settings. Most of the data on OC is limited to preclinical studies and therefore may not accurately reflect the situation in clinical conditions. For the stated reason, the aim of this review was not only to summarize current knowledge of all forms of OC and characterize its role in diabetes mellitus, osteoporosis, osteopetrosis, inflammatory joint diseases, but also to provide new interpretations of its involvement in the management and treatment of aforementioned diseases. In this context, special emphasis was placed on available clinical trials. Significantly lower levels of tOC and ucOC could be associated with the risk of type 2 diabetes mellitus. On the contrary, tOC level does not seem to be a good indicator of high bone turnover status in postmenopausal osteoporosis, osteoarthritis and rheumatoid arthritis. The associations between several pharmacological drugs used to treat all disorders mentioned above and OC levels have also been provided. From this perspective, OC may serve as a medium through which certain medications can influence glucose metabolism, body weight, adiponectin secretion, and synovial inflammation | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Diabetes mellitus | |
| 650 | 4 | |a Inflammatory joint diseases | |
| 650 | 4 | |a Osteocalcin | |
| 650 | 4 | |a Osteopetrosis | |
| 650 | 4 | |a Osteoporosis | |
| 650 | 4 | |a Preclinical and clinical studies | |
| 650 | 7 | |a Osteocalcin |2 NLM | |
| 650 | 7 | |a 104982-03-8 |2 NLM | |
| 650 | 7 | |a Biomarkers |2 NLM | |
| 700 | 1 | |a Biro, Roman |e verfasserin |4 aut | |
| 700 | 1 | |a Kovacova, Veronika |e verfasserin |4 aut | |
| 700 | 1 | |a Babikova, Martina |e verfasserin |4 aut | |
| 700 | 1 | |a Zemanova, Nina |e verfasserin |4 aut | |
| 700 | 1 | |a Mondockova, Vladimira |e verfasserin |4 aut | |
| 700 | 1 | |a Omelka, Radoslav |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of molecular medicine (Berlin, Germany) |d 1995 |g 102(2024), 4 vom: 15. März, Seite 435-452 |w (DE-627)NLM075191725 |x 1432-1440 |7 nnns |
| 773 | 1 | 8 | |g volume:102 |g year:2024 |g number:4 |g day:15 |g month:03 |g pages:435-452 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1007/s00109-024-02418-8 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 102 |j 2024 |e 4 |b 15 |c 03 |h 435-452 | ||